IL17A and arthropathy: Despite a lack of association between baseline levels of the IL-23 effector cytokines IL-17A, IL-17F, and IL-22 with joint disease activity in the current analyses, improvements in this domain were observed through 2 years and correlated with baseline levels of acute phase proteins.